StockNews.AI
RVTY
StockNews.AI
139 days

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

1. FDA approves Revvity's Auto-Pure 2400 platform for TB detection. 2. Launch outside the U.S. in 2024 enhances laboratory productivity.

2m saved
Insight
Article

FAQ

Why Bullish?

The FDA approval may lead to increased adoption and revenue growth, similar to prior approvals that boosted stock prices for biotech firms.

How important is it?

The FDA approval is a significant milestone that opens new revenue streams, enhancing investor confidence.

Why Long Term?

The long-term growth prospects from expanded U.S. market presence will positively influence RVTY's valuation over time.

Related Companies

DXCMILMNABT
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster hig.

Related News